Cure8 research brief
Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered development could help adoption.
Adult patients with IBD, patient advocates, clinicians exploring remote monitoring, and researchers developing digital biomarkers or wearable-based surveillance tools.
This was a nationwide cross-sectional survey of 1,080 people with IBD (age ≥16) distributed via a national patient organization. About 28.7% already used a wearable. Key predictors of willingness to use wearables were shorter disease duration, more frequent flares, younger age, and current wearable use.
The study reports patient-reported preferences and acceptance rather than validation of any specific digital biomarker or device.
How this could affect care Designing wearable-based monitoring with patient input (focus on usability, clear alerts, and minimal time burden) may improve acceptance and adherence if such tools are later validated and integrated into clinical workflows.
This report is based on a survey (patient preferences and acceptability). It does not present clinical validation or accuracy data for wearable-derived biomarkers, and findings reflect respondents in the Netherlands reached via a patient organization.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: ZM—reports grants from ZonMw, Niels Stensen Fellowship, MDL Fonds, Academische Alliantie Fonds (AAF), Top consortium for Knowledge and Innovation (TKI), and Galapagos/Alfasigma; advisory board fees from Johnson & Johnson, Eli Lilly, and Pfizer; and speaker’s fees from Friso-Friesland Campina, Galapagos/Alfasigma, Celltrion, Eli Lilly, and Takeda (all paid to host institution). RW-reports speaker fees and/or an advisory board fees from Ferring, Galapagos, Janssen, and Pfizer. MS-participates in patient advisory boards for Johnson & Johnson/Pfizer and Roche. Crohn & Colitis NL receives contributions from pharmaceutical companies for its activities, which always involve multi-sponsorship. MJP-reports grants from Falk Pharma, the European Commission, ZonMw, Takeda, Johnson & Johnson, AbbVie; and nonfinancial support Falk Pharma, Takeda, Johnson & Johnson, AbbVie, Ferring, Immunodiagnostics, and MSD. The other authors had no conflicts of interest. Ethical approval: This study was approved by the Medical Ethical Committee of Maastricht University Medical Center+ (METC 2025–0398). Participants provided informed consent before filling in the questionnaire. Consent to participate: Informed consent was obtained from all individual participants included in the study.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
